Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Kjell, Bergfeldt"'
Autor:
Caroline Olsson, Tufve Nyholm, Elinore Wieslander, Eva Onjukka, Adalsteinn Gunnlaugsson, Johan Reizenstein, Stefan Johnsson, Ingrid Kristensen, Johan Skönevik, Magnus Karlsson, Ulf Isacsson, Anna Flejmer, Edvard Abel, Fredrik Nordström, Leif Nyström, Kjell Bergfeldt, Björn Zackrisson, Alexander Valdman
Publikováno v:
Physics and Imaging in Radiation Oncology, Vol 11, Iss , Pp 88-91 (2019)
A fundamental problem in radiotherapy is the variation of organ at risk (OAR) volumes. Here we present our initial experience in engaging a large Radiation Oncology (RO) community to agree on national guidelines for OAR delineations. Our project buil
Externí odkaz:
https://doaj.org/article/c2136910012b45ebab9be044271c8f0d
Autor:
Makbule Tambas, Hans Paul van der Laan, Roel J.H.M. Steenbakkers, Jerome Doyen, Beate Timmermann, Ester Orlandi, Morten Hoyer, Karin Haustermans, Petra Georg, Neil G Burnet, Vincent Gregoire, Valentin Calugaru, Esther G.C. Troost, Frank Hoebers, Felipe A. Calvo, Joachim Widder, Fabian Eberle, Marco van Vulpen, Philippe Maingon, Tomasz Skóra, Damien C. Weber, Kjell Bergfeldt, Jiri Kubes, Johannes A. Langendijk
Publikováno v:
Tambas, Makbule; van der Laan, Hans Paul; Steenbakkers, Roel J H M; Doyen, Jerome; Timmermann, Beate; Orlandi, Ester; Hoyer, Morten; Haustermans, Karin; Georg, Petra; Burnet, Neil G; Gregoire, Vincent; Calugaru, Valentin; Troost, Esther G C; Hoebers, Frank; Calvo, Felipe A; Widder, Joachim; Eberle, Fabian; van Vulpen, Marco; Maingon, Philippe; Skóra, Tomasz; ... (2022). Current practice in proton therapy delivery in adult cancer patients across Europe. Radiotherapy and oncology, 167, pp. 7-13. Elsevier 10.1016/j.radonc.2021.12.004
Tambas, M, van der Laan, H P, Steenbakkers, R J H M, Doyen, J, Timmermann, B, Orlandi, E, Hoyer, M, Haustermans, K, Georg, P, Burnet, N G, Gregoire, V, Calugaru, V, Troost, E G C, Hoebers, F, Calvo, F A, Widder, J, Eberle, F, van Vulpen, M, Maingon, P, Skóra, T, Weber, D C, Bergfeldt, K, Kubes, J & Langendijk, J A 2022, ' Current practice in proton therapy delivery in adult cancer patients across Europe ', Radiotherapy and Oncology, vol. 167, pp. 7-13 . https://doi.org/10.1016/j.radonc.2021.12.004
Radiotherapy and Oncology 167(2022), 7-13
Radiotherapy and Oncology, 167, 7-13. ELSEVIER IRELAND LTD
Radiotherapy and Oncology, 167, 7-13. Elsevier Ireland Ltd
Tambas, M, van der Laan, H P, Steenbakkers, R J H M, Doyen, J, Timmermann, B, Orlandi, E, Hoyer, M, Haustermans, K, Georg, P, Burnet, N G, Gregoire, V, Calugaru, V, Troost, E G C, Hoebers, F, Calvo, F A, Widder, J, Eberle, F, van Vulpen, M, Maingon, P, Skóra, T, Weber, D C, Bergfeldt, K, Kubes, J & Langendijk, J A 2022, ' Current practice in proton therapy delivery in adult cancer patients across Europe ', Radiotherapy and Oncology, vol. 167, pp. 7-13 . https://doi.org/10.1016/j.radonc.2021.12.004
Radiotherapy and Oncology 167(2022), 7-13
Radiotherapy and Oncology, 167, 7-13. ELSEVIER IRELAND LTD
Radiotherapy and Oncology, 167, 7-13. Elsevier Ireland Ltd
BACKGROUND AND PURPOSE: Major differences exist among proton therapy (PT) centres regarding PT delivery in adult cancer patient. To obtain insight into current practice in Europe, we performed a survey among European PT centres. MATERIALS AND METHODS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f3f30d56a51b5b5d4dd3f0a57991b87
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85121526339
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85121526339
Autor:
Kjell Bergfeldt, Tufve Nyholm, Alexander Valdman, Stefan Johnsson, Johan Reizenstein, Ulf Isacsson, Ingrid Kristensen, Leif Nyström, Björn Zackrisson, Elinore Wieslander, Anna M. Flejmer, Fredrik Nordström, Eva Onjukka, Edvard Abel, Caroline Olsson, Johan Skönevik, Magnus G. Karlsson, Adalsteinn Gunnlaugsson
Publikováno v:
Physics and Imaging in Radiation Oncology
Physics and Imaging in Radiation Oncology, Vol 11, Iss, Pp 88-91 (2019)
Physics and Imaging in Radiation Oncology, Vol 11, Iss, Pp 88-91 (2019)
A fundamental problem in radiotherapy is the variation of organ at risk (OAR) volumes. Here we present our initial experience in engaging a large Radiation Oncology (RO) community to agree on national guidelines for OAR delineations. Our project buil
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::927e5cb15f1a7bcd1f4d5abdaa911125
https://doi.org/10.1016/j.phro.2019.08.006
https://doi.org/10.1016/j.phro.2019.08.006
Publikováno v:
Bergfeldt, K, Nystrom, H, Witt Nystrom, P & Høyer, M 2020, ' Is there a Nordic solution for the ‘proton-problem’? ', Acta Oncologica, vol. 59, no. 10, pp. 1137-1138 . https://doi.org/10.1080/0284186X.2020.1809705
ACTA ONCOLOGICA, 59(10), 1137-1138. Taylor & Francis Ltd
ACTA ONCOLOGICA, 59(10), 1137-1138. Taylor & Francis Ltd
According to data from the Particle Therapy Co-Operative Group (PTCOG) 20 proton treatment facilities have opened worldwide since 2015, an additional 30 are under construction and as of today there...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1f7913753e596c10d9bd9c5c8c59269
https://doi.org/10.1080/0284186x.2020.1809705
https://doi.org/10.1080/0284186x.2020.1809705
Publikováno v:
Targeted Oncology
Background Although olaparib, the first poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor approved, has been used in routine clinical practice for over three years, little has been published on its uptake, utilization patterns, an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1515947b6c36ee0289b9d99b9a29936d
https://pubmed.ncbi.nlm.nih.gov/30446872
https://pubmed.ncbi.nlm.nih.gov/30446872
Autor:
Roger, Henriksson, Jacob, Järås, Kjell, Bergfeldt, Lena, Sharp, Mona, Ridderheim, Eskil, Degsell, Thomas, Kunze
Publikováno v:
Lakartidningen. 115
New data show a continuously increased five-year survival for almost all analyzed cancer diagnoses since 1990. It has to be emphasized that the figures are uncertain due to the limited number of patients. The variation is huge and the greatest improv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7f3fb403a0a0c2ca55eec737c7b25d74
https://pubmed.ncbi.nlm.nih.gov/29738056
https://pubmed.ncbi.nlm.nih.gov/29738056
Autor:
Thomas, Högberg, Kjell, Bergfeldt, Christer, Borgfeldt, Erik, Holmberg, Elisabeth, Åvall Lundqvist
Publikováno v:
Lakartidningen. 112
Ovarian cancer is the most common cause of death from a gynecologic cancer. Every year around 700 women contracts ovarian cancer in Sweden. The overall survival is among the highest in Europe, but still long term relative survival is only 46%. It is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::1893224b11984f75cdaad25487867364
https://pubmed.ncbi.nlm.nih.gov/26646961
https://pubmed.ncbi.nlm.nih.gov/26646961
Autor:
H. G. M. van der Zanden, Emilia Andersson, G.W. Haasnoot, Tina Dalianis, Lena Kanter, Giuseppe Masucci, Lisa Villabona, Z. Gamzatova, Kjell Bergfeldt, Barbara Seliger, Rolf Kiessling
Publikováno v:
Tissue Antigens. 70:205-213
In solid tumors, human leucocyte antigen (HLA)-A2 has been suggested to be a risk factor and a negative prognostic factor. The HLA-A2 allele in Scandinavia has a high prevalence; it decreases with latitude and also with ovarian cancer mortality in Eu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d387c39e6c8b8bc5c821bc48a1f3738
https://doi.org/10.1111/j.1399-0039.2007.00875.x
https://doi.org/10.1111/j.1399-0039.2007.00875.x
Publikováno v:
Acta obstetricia et gynecologica Scandinavica. 95(4)
We conducted an evaluation of incidence and survival of women with borderline ovarian tumors in Sweden.All women diagnosed with borderline ovarian tumor in the Swedish Cancer Register 1960-2007 (n = 6252) combined with follow up in the Swedish Death
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e37aa945659f46d9887e6d5ac2fe35b2
https://pubmed.ncbi.nlm.nih.gov/26714557
https://pubmed.ncbi.nlm.nih.gov/26714557
Autor:
Liselotte Dahlgren, Giuseppe Masucci, Lisa Villabona, Tina Dalianis, Bo Nillson, Zaynab Gamzatova, Kjell Bergfeldt
Publikováno v:
Gynecologic Oncology. 103:145-150
Objectives. Major histocompatibility complex antigens are mandatory for the immune response, and a genetic imbalance may be linked to tumor escape. We have previously characterized a cluster of ovarian cancer patients with high incidence of HLA-A2. T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4881ff8b16327cf21a61cc436cbd3048
https://doi.org/10.1016/j.ygyno.2006.02.004
https://doi.org/10.1016/j.ygyno.2006.02.004